Gyre Therapeutics (GYRE) Cost of Revenue (2020 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Cost of Revenue of $1.2 million for Q1 2026, up 37.25% year-over-year from $894000.0 in Q1 2025, and down 29.6% quarter-over-quarter from $1.7 million in Q4 2025.
Gyre Therapeutics (GYRE) Cost of Revenue (2020 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Cost of Revenue for 7 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 37.25% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $5.7 million (up 51.33% YoY), while the FY2025 annual figure was $5.4 million, up 39.44% from the prior year.
- Cost of Revenue fell to $1.2 million in Q1 2026 per GYRE's latest filing, from $1.7 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.0 million in Q4 2022 and bottomed at $770000.0 in Q2 2024.
- Historically, Cost of Revenue has averaged $1.3 million across 5 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2023 — Cost of Revenue plunged 68.71% — and 2025, when it surged 69.94%.
- Gyre Therapeutics' Cost of Revenue stood at $4.0 million in 2022, then slumped by 68.71% to $1.2 million in 2023, then decreased by 5.84% to $1.2 million in 2024, then surged by 48.09% to $1.7 million in 2025, then decreased by 29.6% to $1.2 million in 2026.
- Business Quant data shows GYRE's Cost of Revenue at $1.2 million in Q1 2026, $1.7 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 894,000.00 |
| Mar 31, 2025 | 894,000.00 |
| Dec 31, 2024 | 1.18 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 958,000.00 |
| Sep 30, 2024 | 958,000.00 |
| Jun 30, 2024 | 770,000.00 |
| Jun 30, 2024 | 770,000.00 |
| Mar 31, 2024 | 979,000.00 |
| Mar 31, 2024 | 979,000.00 |